BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas
Plain-language summary
This trial is testing brentuximab vedotin (an antibody-drug conjugate targeting CD30) combined with CHP chemotherapy for patients with various types of peripheral T-cell lymphoma (PTCL) who have been newly diagnosed and have not yet received treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to different treatment groups. This trial does not currently have sites in the United States.
Who can join (key eligibility)
- Age 18 Years to 70 Years years
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Doxorubicin (DRUG): doxorubicin 50 mg/m2, day 1 | Vincristine (DRUG): vincristine 1.4 mg/m2, (maximum dose 2 mg) day 1 | Etoposide (DRUG): Etoposide 100 mg/m2, 1-3 days | cyclophosphamide (DRUG): cyclophosphamide 750 mg/m2, day 1 | Prednisone (DRUG): prednisone 100 mg, 1-5 days | Brentuximab Vedotin (Bv) (DRUG): brentuximab vedotin 1.8 mg / kg, day 1
Doxorubicin, Vincristine, Etoposide, cyclophosphamide, Prednisone, Brentuximab Vedotin (Bv)
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details